Yolanda González‐Montes

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

Laura Rosiñol, Albert Oriol, Rafael Ríos et al. · Blood · 2019 · 216 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Laura Rosiñol, Albert Oriol, Rafael Ríos et al. · Blood · 2023 · 57 citations · Full text

Medicine, Hematology, Oncology +14

Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial

Laura Rosiñol, Albert Oriol, Rafael Ríos Tamayo et al. · Blood · 2021 · 24 citations

Medicine, Hematology, Oncology +17

GEM2017FIT Trial: Induction Therapy with Bortezomib-Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus/Minus Daratumumab (D), 18 Cycles, Followed By Consolidation and Maintenance Therapy with Lenalidomide and Daratumumab: Phase III, Multicenter, Randomized Trial for Elderly Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients Aged between 65 and 80 Years

María‐Victoria Mateos, Bruno Paiva, María Teresa Cedena Romero et al. · Blood · 2023 · 24 citations

Medicine, Hematology, Oncology +17

VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study

Laura Rosiñol Dachs, Albert Oriol, Ana Isabel Teruel et al. · Blood · 2018 · 15 citations

Medicine, Hematology, Oncology +15